BR112023018530A2 - Conjugado de ação prolongada, composição farmacêutica e seu uso - Google Patents

Conjugado de ação prolongada, composição farmacêutica e seu uso

Info

Publication number
BR112023018530A2
BR112023018530A2 BR112023018530A BR112023018530A BR112023018530A2 BR 112023018530 A2 BR112023018530 A2 BR 112023018530A2 BR 112023018530 A BR112023018530 A BR 112023018530A BR 112023018530 A BR112023018530 A BR 112023018530A BR 112023018530 A2 BR112023018530 A2 BR 112023018530A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
long action
conjugate
long
action conjugate
Prior art date
Application number
BR112023018530A
Other languages
English (en)
Portuguese (pt)
Inventor
Ram Lee A
Hyeon PARK Da
Lim Oh Euh
Young Kim Jin
Sub Park Jun
Yun Kim Sang
Ho Heo Yong
Yon KIM Yu
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112023018530A2 publication Critical patent/BR112023018530A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112023018530A 2021-03-31 2022-03-31 Conjugado de ação prolongada, composição farmacêutica e seu uso BR112023018530A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210042305 2021-03-31
PCT/KR2022/004620 WO2022211537A1 (ko) 2021-03-31 2022-03-31 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법

Publications (1)

Publication Number Publication Date
BR112023018530A2 true BR112023018530A2 (pt) 2023-10-10

Family

ID=83459706

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018530A BR112023018530A2 (pt) 2021-03-31 2022-03-31 Conjugado de ação prolongada, composição farmacêutica e seu uso

Country Status (15)

Country Link
US (1) US12599675B2 (https=)
EP (1) EP4316528A4 (https=)
JP (1) JP2024512418A (https=)
KR (2) KR102680146B1 (https=)
CN (1) CN116916969A (https=)
AR (1) AR125263A1 (https=)
AU (1) AU2022209248B2 (https=)
BR (1) BR112023018530A2 (https=)
CA (1) CA3205058C (https=)
CL (1) CL2023002504A1 (https=)
IL (1) IL304365B2 (https=)
MX (1) MX2023010926A (https=)
PE (1) PE20250672A1 (https=)
WO (1) WO2022211537A1 (https=)
ZA (1) ZA202307219B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230242607A1 (en) * 2020-07-09 2023-08-03 Eutilex Co., Ltd. Il-2 variants
CN120475959A (zh) 2022-12-23 2025-08-12 韩美药品株式会社 包含免疫活性白细胞介素2类似物缀合物的制剂
EP4678180A1 (en) * 2023-03-07 2026-01-14 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof
WO2024186143A1 (ko) * 2023-03-07 2024-09-12 한미약품 주식회사 암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 면역관문 억제제의 병용 요법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
KR100507796B1 (ko) * 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 peg-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
SG192673A1 (en) * 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
KR102410090B1 (ko) * 2014-02-21 2022-06-16 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 항-ctla-4 항체 또는 항-pd-1 항체와 조합한 il-2r베타-선택적 효현제
PT3172227T (pt) * 2014-07-21 2019-12-06 Delinia Inc Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis
JP6821560B2 (ja) 2014-10-21 2021-01-27 サイクロン ファーマシューティカルズ インターナショナル エルティーディー.Sciclone Pharmaceuticals International Ltd. 免疫刺激剤による癌治療
WO2017052329A1 (en) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性t細胞の増殖のためのインターロイキン-2変異タンパク質
US10696722B2 (en) * 2016-08-10 2020-06-30 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
EP3538548A4 (en) * 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
CN111918665B (zh) * 2018-03-28 2024-11-26 阿森迪斯药物肿瘤股份有限公司 Il-2缀合物
MX2021000801A (es) * 2018-07-24 2021-04-12 BioNTech SE Agonistas de il2.
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
EP3901167A4 (en) * 2018-12-21 2022-11-16 Hanmi Pharm. Co., Ltd. NOVEL IMMUNOSUPRESSIVE INTERLEUKIN 2
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Rna製藥有限公司 Il2激動劑
KR20220044534A (ko) * 2019-08-13 2022-04-08 엘피스 바이오파마슈티컬즈 조작된 인터류킨-2 수용체 베타 효능제

Also Published As

Publication number Publication date
WO2022211537A1 (ko) 2022-10-06
JP2024512418A (ja) 2024-03-19
IL304365A (en) 2023-09-01
KR20240099117A (ko) 2024-06-28
CA3205058C (en) 2024-04-09
KR20220136285A (ko) 2022-10-07
CA3205058A1 (en) 2022-10-26
IL304365B1 (en) 2024-12-01
US20240009317A1 (en) 2024-01-11
CL2023002504A1 (es) 2024-01-26
ZA202307219B (en) 2024-10-30
EP4316528A1 (en) 2024-02-07
IL304365B2 (en) 2025-04-01
US12599675B2 (en) 2026-04-14
MX2023010926A (es) 2023-09-27
KR102680146B1 (ko) 2024-07-04
TW202304521A (zh) 2023-02-01
AU2022209248A1 (en) 2022-10-20
EP4316528A4 (en) 2026-03-11
AR125263A1 (es) 2023-06-28
AU2022209248B2 (en) 2023-06-29
CN116916969A (zh) 2023-10-20
PE20250672A1 (es) 2025-03-04

Similar Documents

Publication Publication Date Title
BR112023018530A2 (pt) Conjugado de ação prolongada, composição farmacêutica e seu uso
BR112021017408A2 (pt) Compostos tricíclicos fundidos úteis como agentes anticancerosos
CL2024003552A1 (es) Anticuerpo anti-ccr8; método de producción; composición farmacéutica; y su uso.
BR112022002496A2 (pt) Compostos deuterados para uso no tratamento de câncer
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
ECSP19000282A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
BR112022000854A2 (pt) Conjugados anticorpo - agonista de sting e seu uso em imunoterapia
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
MX2021015153A (es) Composicion farmaceutica parenteral de agonista dual de glp1/2.
BR112023001471A2 (pt) Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma
BR112023005789A2 (pt) Composição farmacêutica compreendendo conjugado anticorpo-fármaco e uso de composição farmacêutica
ECSP21074141A (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
BR112022013255A2 (pt) Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
BR112019005637A2 (pt) análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
MX2022006082A (es) Composicion aglutinante que incluye un componente de base biologica.
AR106981A1 (es) Una composición antimicrobiana
ECSP22047524A (es) Tieniloxazolonas y an?logos
BR112022020531A2 (pt) Composição farmacêutica
CO2024000763A2 (es) Composiciones y métodos de los anticuerpos anti-pacap
CL2024002184A1 (es) Olanzapina, composiciones de la misma y métodos de uso de la misma
BR112023020843A2 (pt) Composto e seu processo de preparação, e composição farmacêutica
BR112023000585A2 (pt) Composição farmacêutica e uso da mesma
BR112022009658A2 (pt) Composição para preparar alulose e método para preparar alulose com o uso da mesma